Ibiglustat (L-Malic acid)

Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].

Product Specifications

CAS Number

[1629063-78-0]

Product Name Alternative

Venglustat (L-Malic acid) ; SAR402671 (L-Malic acid) ; GZ402671 (L-Malic acid)

UNSPSC

12352005

Hazard Statement

H302, H361, H373

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Ibiglustat_succinate.html

Purity

98.65

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C.OC(C[C@H](O)C(O)=O)=O

Molecular Formula

C24H30FN3O7S

Molecular Weight

523.57

Precautions

H302, H361, H373

References & Citations

[1]Iva Stojkovska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2017.|[2]Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37 (6) :1013-22.|[3]Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11 (1) :20945. Published 2021 Oct 22.|[4]Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10 (1) :86-98.